仑伐替尼治疗中晚期肝癌的研究进展  

Research progress in lenvatinib for the treatment of mid-to-advanced hepatocellular carcinoma

作　　者：吕玲 邹威 陈晓明[1] LV Ling;ZOU Wei;CHEN Xiaoming(Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences),Guangzhou,Guangdong Province 510080,China)

机构地区：[1]广东省人民医院(广东省医学科学院),广州510080

出　　处：《介入放射学杂志》2022年第11期1128-1131,共4页Journal of Interventional Radiology

基　　金：广州市科技基金资助(202201010841)。

摘　　要：仑伐替尼是晚期肝癌的一线分子靶向治疗药物,国内外已有很多关于仑伐替尼疗效相关研究报道,但其影响因素尚不清楚。免疫检查点抑制剂是一类新型抗肿瘤药物,在多种晚期肿瘤治疗中有较好的疗效。本文就仑伐替尼治疗晚肝癌的疗效及其影响因素、联合免疫检查点抑制剂治疗晚期肝癌的研究进展、与中期肝癌标准治疗TACE之间的关系、治疗期间病情进展的治疗方法以及对于REFLECT试验排除患者仑伐替尼的有效性和安全性等方面分别进行介绍,以期对指导肝癌的临床治疗有所帮助。Lenvatinib is an approved first-line molecular targeted therapeutic agent for mid-to-advanced hepatocellular carcinoma(HCC),and many studies on the efficacy of lenvatinib have been reported at home and abroad,but the factors that affect its therapeutic efficacy are still not clear.Immune checkpoint inhibitors(ICI)are novel antitumor drugs,which have already achieved satisfactory effect for a variety of advanced tumors.This paper aims to make a comprehensive review about lenvatinib for the treatment of mid-to-advanced HCC,focusing on its curative effect and influencing factors,the progress in its combination use with ICI for advanced HCC,its relationship to the standard TACE for mid-stage HCC,therapeutic measures for disease progression during treatment,and the effectiveness and safety of lenvatinib in treating patients who have been excluded by REFLECT trial,etc.so as to provide practical guidance for the clinical treatment of HCC.(J Intervent Radiol,2022,31:1128-1131)

关 键 词：肝细胞癌 仑伐替尼 系统治疗 免疫治疗 BCLC B期 进展 

分 类 号：R735.7[医药卫生—肿瘤]